Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT.

Sci Transl Med. 2019 Sep 4;11(508). pii: eaaw8828. doi: 10.1126/scitranslmed.aaw8828.

PMID:
31484791
2.

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.

Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, Ni T, Zhang ZS, Zhang T, Li C, Han L, Zhu Z, Lian F, Wei J, Deng Q, Wang Y, Wunderlich M, Gao Z, Pan G, Zhong D, Zhou H, Zhang N, Gan J, Jiang H, Mulloy JC, Qian Z, Chen J, Yang CG.

Cancer Cell. 2019 Apr 15;35(4):677-691.e10. doi: 10.1016/j.ccell.2019.03.006.

PMID:
30991027
3.

Alternative translation initiation generates the N-terminal truncated form of RUNX1 that retains hematopoietic activity.

Goyama S, Schibler J, Mulloy JC.

Exp Hematol. 2019 Apr;72:27-35. doi: 10.1016/j.exphem.2019.01.008. Epub 2019 Jan 26.

PMID:
30690039
4.

Improved multilineage human hematopoietic reconstitution and function in NSGS mice.

Wunderlich M, Chou FS, Sexton C, Presicce P, Chougnet CA, Aliberti J, Mulloy JC.

PLoS One. 2018 Dec 12;13(12):e0209034. doi: 10.1371/journal.pone.0209034. eCollection 2018.

5.

Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.

Barve A, Casson L, Krem M, Wunderlich M, Mulloy JC, Beverly LJ.

Exp Hematol. 2018 Nov;67:18-31. doi: 10.1016/j.exphem.2018.08.004. Epub 2018 Aug 17.

PMID:
30125602
6.

Cell Polarity and Division Symmetry Analyses in Transformed Blood Cells.

Mizukawa B, O'Brien E, Mulloy JC, Zheng Y.

Methods Mol Biol. 2018;1821:257-266. doi: 10.1007/978-1-4939-8612-5_18.

7.

Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJM, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J.

Nat Commun. 2018 Apr 10;9:16192. doi: 10.1038/ncomms16192.

8.

Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2018 Feb 9;9(1):670. doi: 10.1038/s41467-018-02947-0.

9.

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells.

Eriksson M, Peña-Martínez P, Ramakrishnan R, Chapellier M, Högberg C, Glowacki G, Orsmark-Pietras C, Velasco-Hernández T, Lazarević VL, Juliusson G, Cammenga J, Mulloy JC, Richter J, Fioretos T, Ebert BL, Järås M.

Blood Adv. 2017 Oct 18;1(23):2046-2057. doi: 10.1182/bloodadvances.2017006148. eCollection 2017 Oct 24.

10.

METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification.

Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J.

Cell Stem Cell. 2018 Feb 1;22(2):191-205.e9. doi: 10.1016/j.stem.2017.11.016. Epub 2017 Dec 28.

11.

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.

Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J.

Cell. 2018 Jan 11;172(1-2):90-105.e23. doi: 10.1016/j.cell.2017.11.031. Epub 2017 Dec 14.

12.

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2017 Dec 13;8(1):2099. doi: 10.1038/s41467-017-02290-w. Erratum in: Nat Commun. 2018 Feb 9;9(1):670.

13.

The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Mizukawa B, O'Brien E, Moreira DC, Wunderlich M, Hochstetler CL, Duan X, Liu W, Orr E, Grimes HL, Mulloy JC, Zheng Y.

Blood. 2017 Sep 14;130(11):1336-1346. doi: 10.1182/blood-2016-12-758458. Epub 2017 Aug 4.

14.

A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.

Lin S, Ptasinska A, Chen X, Shrestha M, Assi SA, Chin PS, Imperato MR, Aronow BJ, Zhang J, Weirauch MT, Bonifer C, Mulloy JC.

Blood. 2017 Sep 7;130(10):1213-1222. doi: 10.1182/blood-2016-11-750976. Epub 2017 Jul 14.

15.

The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.

Lin S, Luo RT, Shrestha M, Thirman MJ, Mulloy JC.

Blood. 2017 Aug 17;130(7):903-907. doi: 10.1182/blood-2017-04-777185. Epub 2017 Jun 21.

16.

CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epithelium.

Bertaux-Skeirik N, Wunderlich M, Teal E, Chakrabarti J, Biesiada J, Mahe M, Sundaram N, Gabre J, Hawkins J, Jian G, Engevik AC, Yang L, Wang J, Goldenring JR, Qualls JE, Medvedovic M, Helmrath MA, Diwan T, Mulloy JC, Zavros Y.

J Pathol. 2017 Aug;242(4):463-475. doi: 10.1002/path.4918.

17.

Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.

Kesarwani M, Kincaid Z, Gomaa A, Huber E, Rohrabaugh S, Siddiqui Z, Bouso MF, Latif T, Xu M, Komurov K, Mulloy JC, Cancelas JA, Grimes HL, Azam M.

Nat Med. 2017 Apr;23(4):472-482. doi: 10.1038/nm.4310. Epub 2017 Mar 20.

18.

RUNX1-ETO Leukemia.

Lin S, Mulloy JC, Goyama S.

Adv Exp Med Biol. 2017;962:151-173. doi: 10.1007/978-981-10-3233-2_11. Review.

PMID:
28299657
19.

Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.

Chen X, Clark J, Wunderlich M, Fan C, Davis A, Chen S, Guan JL, Mulloy JC, Kumar A, Zheng Y.

Autophagy. 2017 May 4;13(5):955-966. doi: 10.1080/15548627.2017.1287652. Epub 2017 Feb 15.

20.

Phosphatase PRL2 promotes AML1-ETO-induced acute myeloid leukemia.

Kobayashi M, Chen S, Bai Y, Yao C, Gao R, Sun XJ, Mu C, Twiggs TA, Yu ZH, Boswell HS, Yoder MC, Kapur R, Mulloy JC, Zhang ZY, Liu Y.

Leukemia. 2017 Jun;31(6):1453-1457. doi: 10.1038/leu.2017.67. Epub 2017 Feb 21. No abstract available.

21.

Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.

Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O'Brien MM, Meetei AR, Milne TA, Bonifer C, Mulloy JC, Thirman MJ.

Cancer Cell. 2016 Nov 14;30(5):737-749. doi: 10.1016/j.ccell.2016.10.008.

22.

Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.

Goyama S, Shrestha M, Schibler J, Rosenfeldt L, Miller W, O'Brien E, Mizukawa B, Kitamura T, Palumbo JS, Mulloy JC.

Oncogene. 2017 May 4;36(18):2589-2598. doi: 10.1038/onc.2016.416. Epub 2016 Nov 7.

23.

MISTRG extends PDX modeling to favorable AMLs.

Wunderlich M, Mulloy JC.

Blood. 2016 Oct 27;128(17):2111-2112. No abstract available.

24.

A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Wunderlich M, Stockman C, Devarajan M, Ravishankar N, Sexton C, Kumar AR, Mizukawa B, Mulloy JC.

JCI Insight. 2016 Sep 22;1(15):e88181. doi: 10.1172/jci.insight.88181.

25.

Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.

Lin S, Wei J, Wunderlich M, Chou FS, Mulloy JC.

Oncotarget. 2016 Aug 30;7(35):55939-55950. doi: 10.18632/oncotarget.11093.

26.

Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.

Link KA, Lin S, Shrestha M, Bowman M, Wunderlich M, Bloomfield CD, Huang G, Mulloy JC.

Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9075-80. doi: 10.1073/pnas.1524225113. Epub 2016 Jul 25.

27.

The AS-RBM15 lncRNA enhances RBM15 protein translation during megakaryocyte differentiation.

Tran NT, Su H, Khodadadi-Jamayran A, Lin S, Zhang L, Zhou D, Pawlik KM, Townes TM, Chen Y, Mulloy JC, Zhao X.

EMBO Rep. 2016 Jun;17(6):887-900. doi: 10.15252/embr.201541970. Epub 2016 Apr 26.

28.

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M.

Cell Rep. 2015 Dec 29;13(12):2715-27. doi: 10.1016/j.celrep.2015.12.003. Epub 2015 Dec 17.

29.

UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.

Goyama S, Schibler J, Gasilina A, Shrestha M, Lin S, Link KA, Chen J, Whitman SP, Bloomfield CD, Nicolet D, Assi SA, Ptasinska A, Heidenreich O, Bonifer C, Kitamura T, Nassar NN, Mulloy JC.

Leukemia. 2016 Mar;30(3):728-39. doi: 10.1038/leu.2015.275. Epub 2015 Oct 9.

30.

A ROS-Activatable Agent Elicits Homologous Recombination DNA Repair and Synergizes with Pathway Compounds.

Thowfeik FS, AbdulSalam SF, Wunderlich M, Wyder M, Greis KD, Kadekaro AL, Mulloy JC, Merino EJ.

Chembiochem. 2015 Nov;16(17):2513-21. doi: 10.1002/cbic.201500304. Epub 2015 Nov 2.

31.

Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells.

Glait-Santar C, Desmond R, Feng X, Bat T, Chen J, Heuston E, Mizukawa B, Mulloy JC, Bodine DM, Larochelle A, Dunbar CE.

Stem Cells. 2015 Dec;33(12):3635-42. doi: 10.1002/stem.2208. Epub 2015 Oct 5.

32.

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10786-91. doi: 10.1073/pnas.1422749112. Epub 2015 Aug 10.

33.

MAPK8-mediated stabilization of SP1 is essential for RUNX1-RUNX1T1 - driven leukaemia.

Maiques-Diaz A, Hernando M, Sánchez-López A, Rio-Machin A, Shrestha M, Mulloy JC, Cigudosa JC, Alvarez S.

Br J Haematol. 2016 Mar;172(5):807-10. doi: 10.1111/bjh.13536. Epub 2015 Jun 8. No abstract available.

PMID:
26058961
34.

Xenograft models for normal and malignant stem cells.

Goyama S, Wunderlich M, Mulloy JC.

Blood. 2015 Apr 23;125(17):2630-40. doi: 10.1182/blood-2014-11-570218. Epub 2015 Mar 11. Review.

35.

MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia.

Roychoudhury J, Clark JP, Gracia-Maldonado G, Unnisa Z, Wunderlich M, Link KA, Dasgupta N, Aronow B, Huang G, Mulloy JC, Kumar AR.

Blood. 2015 Apr 16;125(16):2544-52. doi: 10.1182/blood-2014-09-599258. Epub 2015 Mar 4.

36.

Design of a hydrogen peroxide-activatable agent that specifically targets cancer cells.

Vadukoot AK, AbdulSalam SF, Wunderlich M, Pullen ED, Landero-Figueroa J, Mulloy JC, Merino EJ.

Bioorg Med Chem. 2014 Dec 15;22(24):6885-92. doi: 10.1016/j.bmc.2014.10.029. Epub 2014 Oct 30.

37.

Posttranslational modifications of RUNX1 as potential anticancer targets.

Goyama S, Huang G, Kurokawa M, Mulloy JC.

Oncogene. 2015 Jul;34(27):3483-92. doi: 10.1038/onc.2014.305. Epub 2014 Sep 29. Review.

PMID:
25263451
38.

Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J.

J Clin Invest. 2014 Jun;124(6):2762-73. doi: 10.1172/JCI74182. Epub 2014 May 8.

39.

OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.

Wunderlich M, Brooks RA, Panchal R, Rhyasen GW, Danet-Desnoyers G, Mulloy JC.

Blood. 2014 Jun 12;123(24):e134-44. doi: 10.1182/blood-2014-02-556340. Epub 2014 Apr 28.

40.

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G.

Blood. 2014 Mar 13;123(11):1729-38. doi: 10.1182/blood-2013-03-489575. Epub 2014 Jan 21.

41.

Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL.

J Clin Invest. 2014 Jan;124(1):222-36. doi: 10.1172/JCI66005. Epub 2013 Dec 16.

42.

An MDS xenograft model utilizing a patient-derived cell line.

Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT.

Leukemia. 2014 May;28(5):1142-5. doi: 10.1038/leu.2013.372. Epub 2013 Dec 11. No abstract available.

43.

A new inducible model for t(8;21) AML.

Mulloy JC.

EMBO Mol Med. 2013 Dec;5(12):1795-7. doi: 10.1002/emmm.201303483. Epub 2013 Nov 4. No abstract available.

44.

NF-κB: a coordinator for epigenetic regulation by MLL.

Goyama S, Mulloy JC.

Cancer Cell. 2013 Oct 14;24(4):401-2. doi: 10.1016/j.ccr.2013.09.016.

45.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

46.

Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.

Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, Mulloy JC.

J Clin Invest. 2013 Sep;123(9):3876-88. doi: 10.1172/JCI68557. Epub 2013 Aug 27. Erratum in: J Clin Invest. 2013 Nov 1;123(11):4979.

47.

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT.

Cancer Cell. 2013 Jul 8;24(1):90-104. doi: 10.1016/j.ccr.2013.05.006.

48.

TET1 plays an essential oncogenic role in MLL-rearranged leukemia.

Huang H, Jiang X, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, Lin L, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang FC, Mulloy JC, Jin P, Liu PP, Rowley JD, Xu M, He C, Chen J.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11994-9. doi: 10.1073/pnas.1310656110. Epub 2013 Jul 1.

49.

miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.

Chen P, Price C, Li Z, Li Y, Cao D, Wiley A, He C, Gurbuxani S, Kunjamma RB, Huang H, Jiang X, Arnovitz S, Xu M, Hong GM, Elkahloun AG, Neilly MB, Wunderlich M, Larson RA, Le Beau MM, Mulloy JC, Liu PP, Rowley JD, Chen J.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11511-6. doi: 10.1073/pnas.1310144110. Epub 2013 Jun 24.

50.

The rate of spontaneous mutations in human myeloid cells.

Araten DJ, Krejci O, Ditata K, Wunderlich M, Sanders KJ, Zamechek L, Mulloy JC.

Mutat Res. 2013 Sep;749(1-2):49-57. doi: 10.1016/j.mrfmmm.2013.05.004. Epub 2013 Jun 6.

Supplemental Content

Loading ...
Support Center